Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Target Price from Analysts
Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the company, Ratings reports ...
Seeking Alpha29d
Mersana falls after early-stage trial data for lead cancer therapy
Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results from a Phase 1 trial for its lead candidate emiltatug ledadotin (Emi-Le ...
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on ...
Business Insider29d
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...
Morningstar29d
Mersana Shares Rise on Advances With Breast-Cancer Treatment
Mersana Therapeutics shares rose sharply after the biopharmaceutical company won a second Food and Drug Administration fast-track designation for a proposed treatment for breast cancer and ...
Seeking Alpha8d
MRSN Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. (MRSN) stock price is 0.61 and Mersana Therapeutics, Inc. (MRSN) 10-day simple moving average is 0.59. Mersana Therapeutics, Inc. (MRSN) stock price is 0.61 and ...